Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Ris... (all lab reports to determine cardiovascu...)

Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients

Date:4/22/2008

all lab reports to determine cardiovascular disease risk in CMR patients with low to moderate LDL levels and the calculation of apoB in patients with CMR who are on medication. As published in Diabetes Care, the ADA-ACC consensus document also acknowledges the value of directly measured LDL levels when triglyceride levels exceed 200, a frequent occurrence in CMR patients. Extending beyond previous guidelines to specifically address the issue of cardiometabolic risk, the new statement advises clinicians to measure and treat apoB to goal: apoB below 80 (mg/dl) for the highest risk patients or apoB below 90 for high risk patients.

Of note is the fact that the consensus document experts specifically favor apoB, which is considered internationally as the "best reflection of atherogenic particle burden" and does not currently recommend the measurement of nuclear magnetic resonance (NMR) derived LDL-P primarily because of a dearth of clinical evidence and questions about its validity among various ethnic groups. The report also acknowledges that more aggressive control of other lipoprotein parameters may be warranted in those with high concentrations of Lp(a), a particle that is measured in all VAP samples.

The VAP (Vertical Auto Profile) Test is the most accurate and comprehensive cholesterol test available today, reporting 15 separate components of blood cholesterol as opposed to four in a standard test, and is the only cholesterol test to identify markers for Metabolic Syndrome, a precursor for diabetes.

The VAP Test provides physicians with direct measurement of LDL, HDL, and all clinically relevant subclasses, and includes non-HDL, a highly accurate determination of apo B, emerging risk factors (such as Lp(a), LDL pattern, density and size) and precise calculations for LDL components. The test helps to clearly identify individuals with cardiometabolic risk and is able to identify far more patients at risk for heart disease than the standard choles
'/>"/>

4

GOOD

Page: 1 2 3
Related biology technology :

1. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
2. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
3. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
4. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
5. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
6. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
7. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
8. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
9. New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)
10. World Think Tank on Type 1 Diabetes Meets in Miami
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

Post Your Comments:

Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Ris...(all lab reports to determine cardiovascu...)